December 15th 10AM – Briefing on Xtandi March-in Request

Update: Video recording of the press briefing available here: https://www.youtube.com/watch?v=KwqUl7NLMXo) December 15th 10AM – Briefing on Xtandi March-in Request Supporters of the march-in petition to lower the cost of the prostate cancer drug Xtandi will host a virtual press conference… Continue Reading

Eric Sawyer December 13, 2021 Petition to HHS on Xtandi March-in Case

On December 13, 2021, Eric Sawyer filed this petition with the Department of Health and Human Services, asking to join an outstanding march-in petition on the patents for the prostate cancer drug enzalutamide, sold under the brand name Xtandi by… Continue Reading

HHS Asked to Take Up March-in Request of Prostate Cancer Drug Xtandi

(Update: On December 15, 2021 KEI hosted a press briefing regarding the Xtandi march-in request. Video and details available here: https://www.youtube.com/watch?v=KwqUl7NLMXo) On November 18, 2021, Robert Sachs and Clare Love submitted a petition to the Secretary of Health and Human… Continue Reading

KEI letter to Brian Nelson, Office of Terrorism and Financial Intelligence, regarding exceptions to sanctions for medical products

KEI is sending this letter to the Administration today, regarding measures we would like to see undertaken to make the humanitarian exceptions to sanctions work better.  This is a neglected area of policy failure, although there is evidence that the Biden administration… Continue Reading

WIPO SCP 33: Opening statement of Asia and Pacific Group stresses that WIPO “ought to give primacy to the issues of Public Health and Transfer of Technology”

On Monday, 6 December 2021, India delivered an opening statement on behalf of the Asia and Pacific Group (AGP). The Islamic Republic of Iran, Bangladesh, Singapore, Indonesia, United Arab Emirates, and the Republic of Korea are just a few of… Continue Reading

KEI requests an open compulsory license relating to Paxlovid in the Dominican Republic

On Friday, December 3, 2021, KEI requested an open public interest license to allow the exploitation of PF-07321332 (marketed in combination with ritonavir under the brand Paxlovid) in the Dominican Republic. PF-07321332, being developed by Pfizer, has shown promising results… Continue Reading

Letter to Ambassador Tai at USTR regarding bilateral and plurilateral trade agreements and COVID 19

USTR-AmbTai-Bilateral-Plurilateal-agreements-3Dec2021 December 3, 2021 Ambassador Katherine Tai Office of the United States Trade Representative Washington, DC Dear Ambassador Tai, On November 18, 2021, Knowledge Ecology International (KEI) provided comments to USTR on three issues that were important for any WTO… Continue Reading